Toll-like Receptor 9 in breast carcinoma is a good prognostic marker in patients treated with neoadjuvant chemotherapy

Singh, Aradhana; Bandyopadhyay, Arghya; Mukherjee, Narendranath; Basu, Anupam

doi:10.1101/2020.05.28.20114850

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the adjacent epithelial tissue from patient matched tumoral samples trend towards a more negative immunoreactive score (IRS) for TLR9, which may suggest that BC tumors overexpress TLR9 compared to their surrounding tissue. Furthermore, these data agree with previous observations where BC epithelial cells are more TLR9+ than their adjacent tissue or stromal cells (26,33).…”

Section: Discussionsupporting

confidence: 92%

Loss of TLR9 expression in breast cancer tumour cells and its role in the cell cycle

Sible,

Weissman,

Amoyal

et al. 2024

Preprint

View full text Add to dashboard Cite

Toll-like receptor 9 (TLR9), primarily expressed in human dendritic and B cells, recognizes double-stranded DNA motifs from pathogens, initiating an inflammatory response. Recent studies have revealed TLR9’s involvement beyond its conventional role in immune response, notably during the tumorigenesis of various cancers such as head and neck, cervical, and ovarian cancers. Here we show that immunohistochemistry analysis demonstrated significantly lower TLR9 levels in breast cancer tumors compared to normal breast tissue epithelium. Similarly, TLR9 downregulation was also observed in several transformed breast cancer cell lines versus untransformed breast epithelial cell lines. Furthermore, overexpression of TLR9 led to reduced proliferation potential of breast cancer cell associated with activation of senescence as was evident by upregulation of proinflammatory cytokine IL-6, chemokines IL-8 and CXCL1; and growth factor GM-CSF. These findings support TLR9’s regulatory role in mitigating breast cancer and highlight its critical connection between the inflammatory response and tumor immunity.

show abstract

Section: Discussionsupporting

confidence: 92%